TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
CRLBF

Cresco Labs Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

0.6499$ +2.2% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios CRLBF
Line item Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
– – – – – – – 7.1 3.5 3.6 3.7 4.6 5.1 3.9 3.3 2.2 – 0.9 0.9 0.6 0.6 0.6 0.9 0.6 0.9 0.7 0.8 0.4 0.4 0.3 0.7 0.7 0.5 0.5
– – – – – – – 4.9 1.0 1.4 2.1 3.9 5.0 3.2 3.8 2.4 – 0.9 1.0 0.9 0.8 0.7 1.3 0.9 1.4 1.2 1.3 0.7 0.6 0.4 1.1 1.3 1.0 0.9
– – – – – – – – 3.6 3.7 3.5 4.6 5.1 4.1 3.6 2.5 – 1.3 1.3 1.1 1.1 1.1 1.4 1.1 1.4 1.3 1.3 0.9 0.7 0.6 1.1 1.2 1.1 1.1
– – – – – – – – – – – 25.3 31.5 27.4 – – – – 7.5 – – – – – – – – – – – – – 39.4 50.3
– – – – – – – – – – – – – – – – – – – – – 28.9 12.9 8.9 9.0 7.7 7.9 2.9 2.5 2.1 10.7 12.4 – 66.5
– – – – – – – – – – – -4.1% -0.6% -2.5% -3.8% -4.5% – – – – -4.7% 3.5% 7.7% 11.2% 11.1% 13.0% 12.6% 34.2% 40.1% 48.2% 9.4% 8.0% -1.3% 1.5%
Margins
– – – 96.2% 84.5% 87.3% 79.2% 49.9% 50.4% 55.5% 55.1% 60.3% 57.9% 52.9% 51.7% 49.5% 49.8% 50.6% 49.9% 48.3% 46.9% 44.8% 45.2% 47.0% 48.5% 50.4% 51.1% 50.3% 49.7% 49.5% 48.5% 49.5% 50.1% 49.9%
– – – 16.5% -1.9% 2.0% -7.6% -26.7% -24.8% -12.5% 2.2% 11.5% 14.7% 11.9% 10.3% 10.7% 10.8% 11.6% 10.4% 6.8% 4.8% 3.4% 4.2% 8.2% 11.6% 14.8% 15.9% 15.2% 13.4% 12.8% 11.8% 11.7% 11.6% 9.6%
– – – -3.5% -15.1% -15.3% -21.3% -33.6% -25.5% -25.7% -17.4% -16.9% -17.4% -12.6% -45.6% -38.9% -37.0% -37.7% -7.6% -25.2% -25.8% -29.4% -43.6% -23.0% -20.3% -23.1% -9.2% -10.3% -11.9% -6.7% -7.8% -20.6% -20.9% -15.5%
– – – – – – – – – – – -18.8% -3.1% -9.8% -12.5% -10.0% – – – – -2.8% 2.0% 6.7% 6.9% 10.5% 9.6% 10.1% 15.0% 14.5% 12.8% 6.5% 5.3% -0.7% 0.7%
Returns
– – – -1.2% -7.4% -10.4% -13.5% -23.1% -7.3% -10.3% -10.1% -14.3% -17.0% -10.2% -52.7% -42.3% – -40.8% -8.3% -33.8% -35.0% -37.8% -67.4% -35.1% -30.7% -36.9% -14.8% -15.7% -18.1% -10.3% -12.2% -39.8% -39.9% -28.1%
– – – -0.5% -2.4% -3.4% -5.3% -7.0% -3.8% -5.1% -5.1% -6.1% -7.4% -5.6% -22.5% -18.0% – -19.2% -3.7% -13.4% -13.7% -15.6% -24.4% -13.1% -11.4% -12.7% -4.9% -5.5% -6.1% -3.4% -4.1% -11.3% -11.2% -8.0%
Balance Sheet & Debt
– -32 – – -62 -61 -74 – 27 25 -50 33 2.9 133 211 242 – 378 338 350 380 398 383 394 375 386 346 323 215 225 281 359 386 387
– – – – – – – – – – – 0.4 0.0 1.2 – – – – 2.2 – – – – – – – – – – – – – 21.5 28.0
– 66.0% 93.2% 38.0% 32.5% 32.8% 39.0% 30.3% 52.7% 49.2% 50.7% 43.1% 43.5% 55.3% 42.7% 42.4% – 47.0% 44.9% 39.6% 39.1% 41.2% 36.2% 37.2% 37.0% 34.4% 33.0% 35.0% 33.9% 33.0% 33.5% 28.4% 28.0% 28.4%
– 0.0 – – 0.4 0.0 0.0 – 0.2 0.2 0.0 0.3 0.4 0.3 0.7 0.6 – 0.6 0.6 0.7 0.8 0.8 1.0 1.0 1.0 1.1 1.1 1.0 0.8 0.8 0.8 1.2 1.2 1.2
Per Share
– – – – – – – -0.33 -0.22 -0.30 -0.28 -0.37 -0.43 -0.36 -1.29 -1.17 – -1.09 -0.22 -0.70 -0.69 -0.76 -1.01 -0.52 -0.45 -0.50 -0.19 -0.21 -0.24 -0.13 -0.15 -0.38 -0.36 -0.27
– – – – – – – 0.98 0.86 1.15 1.64 2.17 2.46 2.89 2.83 3.00 – 2.90 2.86 2.80 2.66 2.60 2.32 2.27 2.22 2.15 2.12 2.08 2.00 1.93 1.88 1.82 1.73 1.75
– – – – – – – 1.42 3.03 2.87 2.82 2.57 2.52 3.58 2.45 2.76 – 2.67 2.62 2.08 1.96 2.02 1.50 1.49 1.47 1.35 1.31 1.36 1.31 1.25 1.20 0.95 0.91 0.96
– – – – – – – – – – – -0.41 -0.08 -0.28 -0.35 -0.30 – – – – -0.08 0.05 0.15 0.16 0.23 0.21 0.21 0.31 0.29 0.25 0.12 0.10 -0.01 0.01

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?